cytosine has been researched along with Cytomegalovirus in 142 studies
Cytomegalovirus: A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We have recently shown that the artemisinin derivative artemisone, which was screened against malaria in human clinical studies, is a potent inhibitor of human cytomegalovirus (HCMV)." | 7.91 | Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. ( Bar-On, S; Haynes, RK; Lantsberg, D; Laskov, I; Oiknine-Djian, E; Panet, A; Wolf, DG, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 7.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "The methylenecyclopropane nucleoside (MCPN) analogs synguanol and its 6-alkoxy (MBX2168) and 6-alkylthio (MBX1616) derivatives retained good in vitro activities against several common ganciclovir-resistant UL97 kinase variants of human cytomegalovirus." | 7.80 | Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives. ( Bowlin, TL; Chou, S; Komazin-Meredith, G; Williams, JD, 2014) |
| "Human cytomegalovirus (CMV) UL54 DNA polymerase (pol) mutants with known patterns of resistance to current antivirals ganciclovir (GCV), foscarnet (FOS), and cidofovir (CDV) were tested for cyclopropavir (CPV) susceptibility by a standardized reporter-based yield reduction assay." | 7.78 | Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. ( Bowlin, TL; Chou, S; Marousek, G, 2012) |
| "A patient with systemic cytomegalovirus (CMV), including chorioretinitis, received localized and systemic ganciclovir, systemic cidofovir analog, and localized foscarnet." | 7.78 | Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma. ( Chavala, S; Miller, MB; Moss, HB; Say, E, 2012) |
| "Five AIDS patients with cytomegalovirus (CMV) retinitis who had received ganciclovir (GCV) therapy were followed with serial blood sampling to detectchanges both in CMV load and in the genetic composition of genes UL97 and UL54 whilst receiving cidofovir (CDV) therapy." | 7.70 | Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. ( Bowen, EF; Cherrington, JM; Emery, VC; Griffiths, PD; Johnson, MA; Lamy, PD, 1999) |
| "Mutations in both the viral phosphotransferase gene, UL97, and the DNA polymerase gene, UL54, have been shown to confer ganciclovir resistance to cytomegalovirus (CMV)." | 7.69 | High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. ( Cherrington, JM; Freeman, WR; Fuller, MD; Jiles, RE; Smith, IL; Spector, SA, 1997) |
| "Both ganciclovir-sensitive and -resistant human cytomegaloviruses (HCMV) were isolated from a patient with aplastic anemia complicated with CMV retinitis and encephalitis." | 7.69 | Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir. ( Eizuru, Y; Harada, K; Ihara, S; Isashiki, Y; Minamishima, Y, 1997) |
| "HPMPC [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] is a potent inhibitor of human cytomegalovirus (HCMV) replication as determined by conventional tissue culture methods in which the drug concentration remains constant over time." | 7.69 | Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system. ( Hamzeh, FM; Lee, FE; Lietman, PS; Moore, MR, 1994) |
| "The novel acyclic nucleoside phosphonate, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC], is a potent and selective inhibitor of human cytomegalovirus (CMV) replication in cell culture." | 7.68 | Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). ( Balzarini, J; De Clercq, E; Neyts, J; Schols, D; Snoeck, R, 1990) |
| "Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), were evaluated for their effects on rat cytomegalovirus (RCMV)-induced interstitial pneumonitis after allogeneic bone marrow transplantation (BMTx)." | 7.68 | Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine. ( Bruggeman, CA; de Clercq, E; Havenith, M; Stals, FS; Zeytinoglu, A, 1993) |
| "(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC, and two HPMPC-related nucleoside analogs, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, HPMPA, and (2-phosphonylmethoxyethyl)guanine, PMEG, were evaluated for their antiviral activities against guinea pig cytomegalovirus (GPCMV) infection in guinea pig embryo (GPE) cells and human cytomegalovirus (HCMV) infection in human diploid fibroblast (MRC-5) cells." | 7.68 | Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. ( Feng, JS; Fong, CK; Hsiung, GD; Li, SB; Lucia, HL; Yang, ZH, 1990) |
| "The acyclic nucleoside phosphonate analogue (S)-1-[3-hydroxy-2-phosphonylmethoxypropyl]cytosine (HPMPC) is a potent and selective inhibitor of human cytomegalovirus (HCMV) replication and DNA synthesis." | 7.68 | Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. ( Balzarini, J; De Clercq, E; Neyts, J; Snoeck, R, 1991) |
| "Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine [DHPG], were evaluated for their inhibitory effects on human cytomegalovirus (HCMV) replication in human embryonal fibroblasts and on rat cytomegalovirus (RCMV) replication in rat embryonal fibroblasts." | 7.68 | Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo. ( Bruggeman, CA; de Clercq, E; Stals, FS, 1991) |
| "From a series of phosphonylmethoxyalkylpurine and -pyrimidine derivatives, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] emerged as a particularly potent and selective inhibitor of the replication of human cytomegalovirus (CMV)." | 7.67 | (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. ( De Clercq, E; Holy, A; Rosenberg, I; Sakuma, T; Snoeck, R, 1988) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 5.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| " Only the virus recovered from the brains of mice treated with HPMPC at a dosage of 50 mg/kg/week had a slightly decreased susceptibility to HPMPC." | 5.29 | Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. ( De Clercq, E; Neyts, J; Snoeck, R; Sobis, H; Vandeputte, M, 1993) |
| "Ganciclovir (GCV), the therapy of choice for human cytomegalovirus (CMV) infections and foscarnet, a drug used to treat GCV-resistant CMV infections was approved more than twenty years ago." | 4.87 | The search for new therapies for human cytomegalovirus infections. ( Kern, ER; Prichard, MN, 2011) |
| "We have recently shown that the artemisinin derivative artemisone, which was screened against malaria in human clinical studies, is a potent inhibitor of human cytomegalovirus (HCMV)." | 3.91 | Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus. ( Bar-On, S; Haynes, RK; Lantsberg, D; Laskov, I; Oiknine-Djian, E; Panet, A; Wolf, DG, 2019) |
| " We describe a case of a cytomegalovirus (CMV)-seronegative kidney transplant recipient from a CMV-seropositive donor, whose course was complicated during valganciclovir prophylaxis by CMV disease, ultimately progressing to ganciclovir, foscarnet, and cidofovir resistance." | 3.85 | Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report. ( Agrawal, N; Beltran, D; Echenique, IA; Najafian, N; Ramirez-Ruiz, L, 2017) |
| "Eight in vitro selection experiments under brincidofovir pressure elicited the known cytomegalovirus DNA polymerase amino acid substitutions N408K and V812L and the novel exonuclease domain substitutions D413Y, E303D, and E303G, which conferred ganciclovir and cidofovir resistance with 6- to 11-fold resistance to brincidofovir or 17-fold when E303G was combined with V812L." | 3.83 | Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance. ( Chou, S; Ercolani, RJ; Lanier, ER, 2016) |
| "The methylenecyclopropane nucleoside (MCPN) analogs synguanol and its 6-alkoxy (MBX2168) and 6-alkylthio (MBX1616) derivatives retained good in vitro activities against several common ganciclovir-resistant UL97 kinase variants of human cytomegalovirus." | 3.80 | Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives. ( Bowlin, TL; Chou, S; Komazin-Meredith, G; Williams, JD, 2014) |
| "Human cytomegalovirus (CMV) UL54 DNA polymerase (pol) mutants with known patterns of resistance to current antivirals ganciclovir (GCV), foscarnet (FOS), and cidofovir (CDV) were tested for cyclopropavir (CPV) susceptibility by a standardized reporter-based yield reduction assay." | 3.78 | Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure. ( Bowlin, TL; Chou, S; Marousek, G, 2012) |
| "A patient with systemic cytomegalovirus (CMV), including chorioretinitis, received localized and systemic ganciclovir, systemic cidofovir analog, and localized foscarnet." | 3.78 | Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma. ( Chavala, S; Miller, MB; Moss, HB; Say, E, 2012) |
| "Diverse mutations in the cytomegalovirus (CMV) DNA polymerase (pol) gene confer resistance to one or more of the antiviral drugs ganciclovir, foscarnet or cidofovir." | 3.74 | Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus. ( Chou, S; Li, S; Marousek, G; Weinberg, A, 2008) |
| "A human cytomegalovirus (CMV) UL54 pol exonuclease domain II mutation, D413A, found in a clinical specimen, conferred ganciclovir (GCV) and cidofovir resistance but not foscarnet resistance when incorporated into laboratory strain T2294." | 3.74 | Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. ( Chou, S; Marousek, GI, 2008) |
| "Emergence of human cytomegalovirus (HCMV) resistance to ganciclovir in solid-organ transplant recipients has been found to be mostly associated with primary HCMV infection." | 3.72 | Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. ( Baldanti, F; Campanini, G; Comolli, G; Gerna, G; Lilleri, D; Ridolfo, AL; Rusconi, S, 2004) |
| "Twenty derivatives of aphidicolin were tested against HSV (herpes simplex virus), HCMV (human cytomegalovirus) and adenovirus in vitro." | 3.71 | In vitro antiviral activity of aphidicolin and its derivates. Synergistic effects of aphidicolin with other antiviral drugs. ( Cinatl, J; Doerr, HW; Kreuter, J; Langer, K; Michaelis, M; Rabenau, H; Vogel, JU, 2002) |
| "A patient with AIDS and cytomegalovirus (CMV) retinitis received ganciclovir and foscarnet for 20 and 5 months, respectively, with evidence of periodic disease progression." | 3.70 | A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. ( Chou, S; Drew, WL; Miner, RC, 2000) |
| "Five AIDS patients with cytomegalovirus (CMV) retinitis who had received ganciclovir (GCV) therapy were followed with serial blood sampling to detectchanges both in CMV load and in the genetic composition of genes UL97 and UL54 whilst receiving cidofovir (CDV) therapy." | 3.70 | Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. ( Bowen, EF; Cherrington, JM; Emery, VC; Griffiths, PD; Johnson, MA; Lamy, PD, 1999) |
| "In a human immunodeficiency virus-infected subject, cytomegalovirus (CMV) isolated 9 months after the patient began oral ganciclovir prophylaxis was resistant to ganciclovir and cidofovir and contained mutations in both UL97 and Pol coding regions." | 3.69 | Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. ( Chou, S; Drew, WL; Follansbee, SE; Guentzel, S; Lalezari, JP; Marousek, G; Miner, RC; Poscher, ME, 1997) |
| "Drug-resistant human cytomegalovirus (HCMV) strains were selected in human embryonic lung (HEL) fibroblasts under pressure of the (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC) and adenine (HPMPA), the 2-phosphonylmethoxyethyl (PME) derivative of 2,6-diaminopurine (PMEDAP), ganciclovir (GCV), acyclovir (ACV), and foscarnet (PFA)." | 3.69 | Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. ( Andrei, G; De Clercq, E; Snoeck, R, 1996) |
| "Both ganciclovir-sensitive and -resistant human cytomegaloviruses (HCMV) were isolated from a patient with aplastic anemia complicated with CMV retinitis and encephalitis." | 3.69 | Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir. ( Eizuru, Y; Harada, K; Ihara, S; Isashiki, Y; Minamishima, Y, 1997) |
| "HPMPC [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine] is a potent inhibitor of human cytomegalovirus (HCMV) replication as determined by conventional tissue culture methods in which the drug concentration remains constant over time." | 3.69 | Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system. ( Hamzeh, FM; Lee, FE; Lietman, PS; Moore, MR, 1994) |
| "Mutations in both the viral phosphotransferase gene, UL97, and the DNA polymerase gene, UL54, have been shown to confer ganciclovir resistance to cytomegalovirus (CMV)." | 3.69 | High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. ( Cherrington, JM; Freeman, WR; Fuller, MD; Jiles, RE; Smith, IL; Spector, SA, 1997) |
| "Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine [DHPG], were evaluated for their inhibitory effects on human cytomegalovirus (HCMV) replication in human embryonal fibroblasts and on rat cytomegalovirus (RCMV) replication in rat embryonal fibroblasts." | 3.68 | Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo. ( Bruggeman, CA; de Clercq, E; Stals, FS, 1991) |
| "The acyclic nucleoside phosphonate analogue (S)-1-[3-hydroxy-2-phosphonylmethoxypropyl]cytosine (HPMPC) is a potent and selective inhibitor of human cytomegalovirus (HCMV) replication and DNA synthesis." | 3.68 | Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro. ( Balzarini, J; De Clercq, E; Neyts, J; Snoeck, R, 1991) |
| "Two antiviral compounds, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG), were evaluated for their effects on rat cytomegalovirus (RCMV)-induced interstitial pneumonitis after allogeneic bone marrow transplantation (BMTx)." | 3.68 | Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine. ( Bruggeman, CA; de Clercq, E; Havenith, M; Stals, FS; Zeytinoglu, A, 1993) |
| "Phosphonylmethoxyalkylpurines and -pyrimidines, particularly (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) and (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine (HPMPA) and their cyclic forms (cHPMPC, cHPMPA) and the 3-deaza analogue of HPMPA (HPMPc3A) are selective and potent inhibitors of human cytomegalovirus (CMV) replication in vitro." | 3.68 | Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique. ( Andrei, G; De Clercq, E; Neyts, J; Schols, D; Snoeck, R, 1991) |
| "1-(S)-(3-Hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits efficiently human cytomegalovirus (HCMV) replication." | 3.68 | Pretreatment of the host cell with 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) is sufficient for its antiviral effect. ( Holý, A; Otová, B; Votruba, I, 1992) |
| "(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, HPMPC, and two HPMPC-related nucleoside analogs, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, HPMPA, and (2-phosphonylmethoxyethyl)guanine, PMEG, were evaluated for their antiviral activities against guinea pig cytomegalovirus (GPCMV) infection in guinea pig embryo (GPE) cells and human cytomegalovirus (HCMV) infection in human diploid fibroblast (MRC-5) cells." | 3.68 | Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. ( Feng, JS; Fong, CK; Hsiung, GD; Li, SB; Lucia, HL; Yang, ZH, 1990) |
| "The novel acyclic nucleoside phosphonate, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC], is a potent and selective inhibitor of human cytomegalovirus (CMV) replication in cell culture." | 3.68 | Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). ( Balzarini, J; De Clercq, E; Neyts, J; Schols, D; Snoeck, R, 1990) |
| " By comparison, HPMPC exhibited greater activity than ACV against a thymidine kinase deficient strain of HSV 1 and was more potent than ganciclovir [DHPG, 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine] against human cytomegalovirus." | 3.67 | Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. ( Bronson, JJ; Ghazzouli, I; Hitchcock, MJ; Martin, JC; Webb, RR, 1989) |
| "From a series of phosphonylmethoxyalkylpurine and -pyrimidine derivatives, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] emerged as a particularly potent and selective inhibitor of the replication of human cytomegalovirus (CMV)." | 3.67 | (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication. ( De Clercq, E; Holy, A; Rosenberg, I; Sakuma, T; Snoeck, R, 1988) |
| " The most common adverse events were mild gastrointestinal events and asymptomatic, transient, and reversible elevations in serum transaminases." | 2.84 | Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox. ( Brundage, T; Chittick, G; Morrison, M; Nichols, WG, 2017) |
| "Diarrhea was dose-limiting in this population at a dose of 200 mg twice weekly." | 2.78 | CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. ( Boeckh, M; Brundage, TM; Godkin, S; Marty, FM; Momméja-Marin, H; Mullane, KM; Papanicolaou, GA; Robertson, AT; Rowley, SD; Vance, E; Winston, DJ, 2013) |
| " The most advantageous pharmacokinetic profile and the best oral bioavailability were found in tyrosinebased prodrugs." | 2.55 | Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals. ( Krecmerova, M, 2017) |
| " The emergence of drug resistance may be reduced by optimization of host immunity, use of potent antiviral drug regimens, and adherence to dosing regimens that adequately suppress viral replication." | 2.41 | Cytomegalovirus drug resistance and clinical implications. ( Chou, SW, 2001) |
| "We reviewed data of 4 cancer patients with resistant CMV or herpes simplex virus (HSV) infections and were treated with brincidofovir under emergency IND application." | 1.43 | Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. ( Ariza-Heredia, EJ; Chemaly, RF; El Chaer, F; El-Haddad, D; Gulbis, AM; Mulanovich, VE; Shah, DP; Shpall, EJ; Vanichanan, J, 2016) |
| "A severely T-cell-depleted patient with chronic lymphocytic leukemia developed CMV pneumonia and high plasma viral loads that were poorly responsive to antiviral therapy." | 1.40 | Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. ( Chou, S; Ercolani, RJ; Lefterova, MI; Pinsky, BA; Sahoo, MK; Strasfeld, LM, 2014) |
| " (l)-Tyr-NH-i-Bu cHPMPA (11) was converted in rat or mouse plasma solely to two active metabolites and had significantly enhanced oral bioavailability vs parent drug 1 in a mouse model (39% vs <5%)." | 1.37 | Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies. ( Borysko, KZ; Breitenbach, JM; Collins, M; Drach, JC; Hilfinger, JM; Kashemirov, BA; Krylov, IS; McKenna, CE; Peterson, LW; Serpi, M; Zakharova, VM, 2011) |
| "Leflunomide was selected as a last resort to avoid the nephrotoxicity of cidofovir." | 1.34 | Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation. ( Abdelhalim, A; Almyroudis, NG; Battiwalla, M; Becker, J; Elefante, A; McCarthy, A; McCarthy, PL; Paplham, P; Segal, BH; Smith, P, 2007) |
| "To improve the oral bioavailability of cidofovir (CDV), a series of ether lipid ester prodrugs were synthesized and evaluated for activity against murine cytomegalovirus (MCMV) infection." | 1.32 | Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. ( Beadle, JR; Collins, DJ; Hostetler, KY; Kern, ER; Quenelle, DC; Wan, WB, 2004) |
| " In case of response with a decreasing number of pp65-positive leukocytes, CDV was scheduled in a dosage of 5 mg/kg body weight once a week for 2 weeks followed by maintenance therapy every 2 weeks in an outpatient setting." | 1.31 | Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. ( Bandt, D; Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Geissler, G; Helwig, A; Platzbecker, U; Plettig, R; Rethwilm, A; Schuler, U; Thiede, C, 2001) |
| "This iritis was characterized by infiltration of acute inflammatory cells mixed with cytomegalic cells, which was confirmed by CMV-specific immunohistochemical staining." | 1.30 | Cytomegalovirus iritis. ( Avila, CP; Cheng, L; Freeman, WR; Keefe, KS; Macdonald, JC; Rao, NA, 1998) |
| "Eleven AIDS patients receiving HAART with healed CMV retinitis in whom CMV-specific maintenance therapy was discontinued were studied." | 1.30 | Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. ( Freeman, WR; Karavellas, MP; Macdonald, JC; Morse, LS; Reed, JB; Torriani, FJ, 1998) |
| " Only the virus recovered from the brains of mice treated with HPMPC at a dosage of 50 mg/kg/week had a slightly decreased susceptibility to HPMPC." | 1.29 | Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice. ( De Clercq, E; Neyts, J; Snoeck, R; Sobis, H; Vandeputte, M, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (6.34) | 18.7374 |
| 1990's | 48 (33.80) | 18.2507 |
| 2000's | 47 (33.10) | 29.6817 |
| 2010's | 36 (25.35) | 24.3611 |
| 2020's | 2 (1.41) | 2.80 |
| Authors | Studies |
|---|---|
| Demin, MV | 2 |
| Tikhomirov, DS | 2 |
| Tupoleva, TA | 2 |
| Filatov, FP | 2 |
| Huston, J | 1 |
| Curtis, S | 1 |
| Egelund, EF | 1 |
| Oiknine-Djian, E | 1 |
| Bar-On, S | 1 |
| Laskov, I | 1 |
| Lantsberg, D | 1 |
| Haynes, RK | 1 |
| Panet, A | 1 |
| Wolf, DG | 1 |
| Bruminhent, J | 1 |
| Rotjanapan, P | 1 |
| Watcharananan, SP | 1 |
| Echenique, IA | 1 |
| Beltran, D | 1 |
| Ramirez-Ruiz, L | 1 |
| Najafian, N | 1 |
| Agrawal, N | 1 |
| Mazzaglia, A | 1 |
| Scala, A | 1 |
| Sortino, G | 1 |
| Zagami, R | 1 |
| Zhu, Y | 1 |
| Sciortino, MT | 1 |
| Pennisi, R | 1 |
| Pizzo, MM | 1 |
| Neri, G | 1 |
| Grassi, G | 1 |
| Piperno, A | 1 |
| O'Brien, MS | 1 |
| Markovich, KC | 1 |
| Selleseth, D | 1 |
| DeVita, AV | 1 |
| Sethna, P | 1 |
| Gentry, BG | 1 |
| Marty, FM | 2 |
| Winston, DJ | 2 |
| Chemaly, RF | 2 |
| Mullane, KM | 2 |
| Shore, TB | 1 |
| Papanicolaou, GA | 2 |
| Chittick, G | 2 |
| Brundage, TM | 2 |
| Wilson, C | 2 |
| Morrison, ME | 1 |
| Foster, SA | 1 |
| Nichols, WG | 2 |
| Boeckh, MJ | 1 |
| James, SH | 1 |
| Price, NB | 1 |
| Hartline, CB | 5 |
| Lanier, ER | 3 |
| Prichard, MN | 4 |
| Rowley, SD | 1 |
| Vance, E | 1 |
| Robertson, AT | 1 |
| Godkin, S | 1 |
| Momméja-Marin, H | 2 |
| Boeckh, M | 3 |
| Fischer, L | 3 |
| Laib Sampaio, K | 1 |
| Jahn, G | 3 |
| Hamprecht, K | 3 |
| Göhring, K | 3 |
| Chou, S | 12 |
| Komazin-Meredith, G | 1 |
| Williams, JD | 1 |
| Bowlin, TL | 3 |
| Piret, J | 1 |
| Boivin, G | 2 |
| Gregg, K | 1 |
| Hakki, M | 1 |
| Kaul, DR | 1 |
| Sellar, RS | 1 |
| Peggs, KS | 2 |
| Ercolani, RJ | 2 |
| Sahoo, MK | 1 |
| Lefterova, MI | 1 |
| Strasfeld, LM | 1 |
| Pinsky, BA | 1 |
| Florescu, DF | 1 |
| Keck, MA | 1 |
| Griffiths, P | 1 |
| Lumley, S | 1 |
| Murphy, WJ | 1 |
| Sampaio, KL | 2 |
| Andouard, D | 1 |
| Mazeron, MC | 3 |
| Ligat, G | 1 |
| Couvreux, A | 1 |
| Pouteil-Noble, C | 1 |
| Cahen, R | 1 |
| Yasdanpanah, Y | 1 |
| Deering, M | 1 |
| Viget, N | 1 |
| Alain, S | 2 |
| Hantz, S | 1 |
| Foster, S | 1 |
| Brundage, T | 2 |
| Kleiboeker, S | 1 |
| Colville, D | 1 |
| Imrich, E | 1 |
| Hofmann, J | 1 |
| Lilleri, D | 2 |
| Gerna, G | 4 |
| Camargo, JF | 1 |
| Morris, MI | 1 |
| Abbo, LM | 1 |
| Simkins, J | 1 |
| Saneeymehri, S | 1 |
| Alencar, MC | 1 |
| Lekakis, LJ | 1 |
| Komanduri, KV | 1 |
| El-Haddad, D | 1 |
| El Chaer, F | 1 |
| Vanichanan, J | 1 |
| Shah, DP | 1 |
| Ariza-Heredia, EJ | 1 |
| Mulanovich, VE | 1 |
| Gulbis, AM | 1 |
| Shpall, EJ | 1 |
| Morrison, M | 1 |
| Krecmerova, M | 2 |
| Wen, YN | 1 |
| Zhang, ZF | 1 |
| Liu, NN | 1 |
| Andrei, G | 6 |
| Snoeck, R | 13 |
| Xiang, YH | 1 |
| Schols, D | 5 |
| Chen, X | 1 |
| Zhang, ZY | 1 |
| Zhang, QS | 1 |
| Wu, QP | 1 |
| Oshima, K | 1 |
| Kanda, Y | 1 |
| Kako, S | 1 |
| Asano-Mori, Y | 1 |
| Watanabe, T | 1 |
| Motokura, T | 1 |
| Chiba, S | 1 |
| Shiraki, K | 1 |
| Kurokawa, M | 1 |
| Péter, A | 1 |
| Telkes, G | 1 |
| Varga, M | 1 |
| Járay, J | 1 |
| Lurain, NS | 1 |
| Kern, ER | 10 |
| Tichý, T | 1 |
| Dračínský, M | 1 |
| Holý, A | 3 |
| Balzarini, J | 5 |
| Peterson, LW | 2 |
| Kim, JS | 1 |
| Kijek, P | 1 |
| Mitchell, S | 1 |
| Hilfinger, J | 1 |
| Breitenbach, J | 1 |
| Borysko, K | 1 |
| Drach, JC | 2 |
| Kashemirov, BA | 2 |
| McKenna, CE | 2 |
| Zakharova, VM | 1 |
| Serpi, M | 1 |
| Krylov, IS | 1 |
| Breitenbach, JM | 1 |
| Borysko, KZ | 1 |
| Collins, M | 1 |
| Hilfinger, JM | 1 |
| Marousek, G | 3 |
| Moss, HB | 1 |
| Chavala, S | 1 |
| Say, E | 1 |
| Miller, MB | 1 |
| Goldsmith, PM | 1 |
| Husain, MM | 1 |
| Carmichael, A | 1 |
| Zhang, H | 1 |
| Middleton, SJ | 1 |
| Beadle, JR | 6 |
| Hartline, C | 2 |
| Aldern, KA | 1 |
| Rodriguez, N | 1 |
| Harden, E | 1 |
| Hostetler, KY | 6 |
| Zaia, JA | 2 |
| Lee, JY | 1 |
| Oh, CH | 1 |
| Ko, OH | 1 |
| Hong, JH | 1 |
| van der Strate, BW | 1 |
| De Boer, FM | 1 |
| Bakker, HI | 1 |
| Meijer, DK | 1 |
| Molema, G | 1 |
| Harmsen, MC | 1 |
| Bravo, FJ | 3 |
| Bourne, N | 1 |
| Schleiss, MR | 1 |
| Bernstein, DI | 3 |
| Baldanti, F | 3 |
| Campanini, G | 1 |
| Comolli, G | 1 |
| Ridolfo, AL | 1 |
| Rusconi, S | 1 |
| Ducancelle, A | 1 |
| Belloc, S | 1 |
| Scieux, C | 2 |
| Malphettes, M | 1 |
| Petit, F | 1 |
| Brouet, JC | 1 |
| Sanson Le Pors, MJ | 1 |
| Fryer, JF | 1 |
| Griffiths, PD | 2 |
| Emery, VC | 3 |
| Clark, DA | 1 |
| Lurain, N | 1 |
| Bidanset, DJ | 3 |
| Rybak, RJ | 2 |
| Wan, WB | 5 |
| Jenke, AC | 1 |
| Scinteie, MF | 1 |
| Stehle, IM | 1 |
| Lipps, HJ | 1 |
| Collins, DJ | 2 |
| Quenelle, DC | 2 |
| Herget, T | 1 |
| Freitag, M | 1 |
| Morbitzer, M | 1 |
| Kupfer, R | 1 |
| Stamminger, T | 1 |
| Marschall, M | 1 |
| Ciesla, SL | 1 |
| Valiaeva, N | 1 |
| Scott, GM | 2 |
| Ng, HL | 1 |
| Morton, CJ | 1 |
| Parker, MW | 1 |
| Rawlinson, WD | 2 |
| Williams-Aziz, SL | 1 |
| Harden, EA | 1 |
| Daily, SL | 1 |
| Kushner, NL | 1 |
| Gilbert, C | 1 |
| De Clercq, E | 16 |
| Cardin, RD | 2 |
| Drew, WL | 5 |
| Miner, RC | 3 |
| Marousek, GI | 2 |
| Weinberg, A | 2 |
| Battiwalla, M | 1 |
| Paplham, P | 1 |
| Almyroudis, NG | 1 |
| McCarthy, A | 1 |
| Abdelhalim, A | 1 |
| Elefante, A | 1 |
| Smith, P | 1 |
| Becker, J | 1 |
| McCarthy, PL | 1 |
| Segal, BH | 1 |
| Eizuru, Y | 2 |
| Pettway, LR | 1 |
| Li, S | 1 |
| Gangopadhyay, NN | 1 |
| Whitley, RJ | 1 |
| Chatterjee, S | 1 |
| Moore, MR | 1 |
| Hamzeh, FM | 1 |
| Lee, FE | 1 |
| Lietman, PS | 1 |
| Neyts, J | 7 |
| Ma, TW | 1 |
| Min, JM | 1 |
| Zhang, LH | 1 |
| Stals, FS | 3 |
| Zeytinoglu, A | 1 |
| Havenith, M | 1 |
| Bruggeman, CA | 3 |
| Sobis, H | 1 |
| Vandeputte, M | 1 |
| Cherrington, JM | 6 |
| Miner, R | 2 |
| Hitchcock, MJ | 3 |
| Lalezari, JP | 3 |
| Xiong, X | 2 |
| Smith, JL | 2 |
| Kim, C | 1 |
| Huang, ES | 2 |
| Chen, MS | 2 |
| Flaherty, JF | 1 |
| Lea, AP | 1 |
| Bryson, HM | 1 |
| Lagneaux, L | 2 |
| Delforge, A | 2 |
| Bosmans, E | 1 |
| De Clereq, E | 1 |
| Stryckmans, P | 2 |
| Bron, D | 2 |
| Kuppermann, BD | 1 |
| Harada, K | 1 |
| Isashiki, Y | 1 |
| Ihara, S | 1 |
| Minamishima, Y | 1 |
| Smith, IL | 2 |
| Jiles, RE | 1 |
| Fuller, MD | 4 |
| Freeman, WR | 4 |
| Spector, SA | 2 |
| Guentzel, S | 1 |
| Follansbee, SE | 1 |
| Poscher, ME | 1 |
| Pérez, JL | 1 |
| Takahashi, K | 1 |
| Taskintuna, I | 1 |
| Rahhal, FM | 1 |
| Powell, HC | 1 |
| Ai, E | 1 |
| Mueller, AJ | 1 |
| Biron, KK | 1 |
| Macdonald, JC | 2 |
| Torriani, FJ | 1 |
| Morse, LS | 1 |
| Karavellas, MP | 1 |
| Reed, JB | 1 |
| Cihlar, T | 2 |
| Mulato, AS | 1 |
| Houhou-Fidouh, N | 1 |
| Dewilde, A | 1 |
| Thouvenot, D | 1 |
| Aissa, N | 1 |
| Carquin, J | 1 |
| Freymuth, F | 1 |
| Jabs, DA | 1 |
| Enger, C | 1 |
| Dunn, JP | 1 |
| Forman, M | 1 |
| Hubbard, L | 1 |
| Lamy, PD | 2 |
| Nuessle, S | 1 |
| Cheng, L | 1 |
| Rao, NA | 1 |
| Keefe, KS | 1 |
| Avila, CP | 1 |
| Bedard, J | 2 |
| May, S | 2 |
| Lis, M | 1 |
| Tryphonas, L | 1 |
| Drach, J | 1 |
| Huffman, J | 1 |
| Sidwell, R | 1 |
| Chan, L | 1 |
| Bowlin, T | 1 |
| Rando, R | 1 |
| Barbeau, D | 1 |
| Yuen, L | 1 |
| Rando, RF | 1 |
| Buchanan, J | 1 |
| Davis, LJ | 1 |
| Bowen, EF | 1 |
| Johnson, MA | 1 |
| Safrin, S | 1 |
| Cherrington, J | 1 |
| Jaffe, HS | 1 |
| Papastamopoulos, V | 1 |
| Botsis, C | 1 |
| Paparizos, VA | 1 |
| Kyriakis, KP | 1 |
| Zagoraios, Y | 1 |
| Stavrianeas, NG | 1 |
| Martinez, A | 1 |
| Esteban, A | 1 |
| Castro, A | 1 |
| Gil, C | 1 |
| Conde, S | 1 |
| Einsele, H | 1 |
| Hebart, H | 1 |
| Held, TK | 1 |
| Biel, SS | 1 |
| Nitsche, A | 1 |
| Kurth, A | 1 |
| Chen, S | 1 |
| Gelderblom, HR | 1 |
| Siegert, W | 1 |
| Ketteler, M | 1 |
| Preuschof, L | 1 |
| Mertz, A | 1 |
| Stöffler-Meilicke, M | 1 |
| Schäfer, H | 1 |
| Distler, A | 1 |
| Offermann, G | 1 |
| Crippa, F | 1 |
| Corey, L | 1 |
| Chuang, EL | 1 |
| Sale, G | 1 |
| Bruning, JH | 1 |
| Persoons, M | 1 |
| Lemström, K | 1 |
| Platzbecker, U | 1 |
| Bandt, D | 1 |
| Thiede, C | 1 |
| Helwig, A | 1 |
| Freiberg-Richter, J | 1 |
| Schuler, U | 1 |
| Plettig, R | 1 |
| Geissler, G | 1 |
| Rethwilm, A | 1 |
| Ehninger, G | 1 |
| Bornhäuser, M | 1 |
| Blanchet, KD | 1 |
| Kiehl, MG | 1 |
| Basara, N | 1 |
| Castagnola, E | 1 |
| Miano, M | 1 |
| Morreale, G | 1 |
| Cristina, E | 1 |
| Chierici, M | 1 |
| Lanino, E | 1 |
| Bhorade, SM | 1 |
| Sandesara, C | 1 |
| Garrity, ER | 1 |
| Vigneswaran, WT | 1 |
| Norwick, L | 1 |
| Alkan, S | 1 |
| Husain, AN | 1 |
| McCabe, MA | 1 |
| Yeldandi, V | 1 |
| Chakrabarti, S | 1 |
| Collingham, KE | 1 |
| Osman, H | 1 |
| Fegan, CD | 1 |
| Milligan, DW | 1 |
| Chou, SW | 1 |
| Bosi, A | 1 |
| Bartolozzi, B | 1 |
| Vannucchi, AM | 1 |
| Orsi, A | 1 |
| Guidi, S | 1 |
| Rossi Ferrini, P | 1 |
| Vogel, JU | 2 |
| Michaelis, M | 2 |
| Blaheta, RA | 1 |
| Rabenau, HF | 1 |
| Kreuter, J | 2 |
| Cinatl, J | 2 |
| Doerr, HW | 2 |
| Langer, K | 1 |
| Rabenau, H | 1 |
| Kilpatrick, BA | 1 |
| Otová, B | 1 |
| Votruba, I | 1 |
| Martin, JC | 3 |
| Himpens, B | 1 |
| Shigeta, S | 1 |
| Konno, K | 1 |
| Baba, M | 1 |
| Yokota, T | 1 |
| Kim, CU | 1 |
| Luh, BY | 1 |
| Li, SB | 1 |
| Yang, ZH | 1 |
| Feng, JS | 1 |
| Fong, CK | 1 |
| Lucia, HL | 1 |
| Hsiung, GD | 1 |
| Van der Auwera, P | 1 |
| Bronson, JJ | 1 |
| Ghazzouli, I | 1 |
| Webb, RR | 1 |
| Sakuma, T | 1 |
| Rosenberg, I | 1 |
| Mosmann, TR | 2 |
| Hudson, JB | 2 |
| Plummer, G | 1 |
| Goodheart, CR | 1 |
| Henson, D | 1 |
| Bowling, CP | 1 |
| Lee, LF | 1 |
| Roizman, B | 1 |
| Spear, PG | 1 |
| Kieff, ED | 1 |
| Burmester, BR | 1 |
| Nazerian, K | 1 |
| Ludwig, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients[NCT01769170] | Phase 3 | 452 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients[NCT00942305] | Phase 2 | 239 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The incidence of clinically significant cytomegalovirus (CMV) infection through Week 14.~Blood and urine for virologic evaluations were collected at screening, pre-dose on the first day of study drug administration, and at pre-specified intervals throughout the treatment phases of the study and sent to a designated central virology laboratory for analysis. Blood samples were used for real-time assay of CMV viremia in plasma using a qPCR assay. Urine samples were stored for possible future retrospective analyses of CMV." (NCT01769170)
Timeframe: 14 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Brincidofovir | 74 |
| Placebo | 57 |
"Clinically significant cytomegalovirus (CMV) infection was defined by either of the following outcomes:~Onset of CMV end-organ disease; or~Initiation of anti-CMV-specific preemptive therapy based on documented CMV viremia (as measured by the central virology laboratory) and the clinical condition of the subject.~CMV viremia (i.e., the measurement of CMV DNA in plasma) was determined by the designated central virology laboratory at all scheduled visits via quantitative polymerase chain reaction (qPCR) testing using the Roche COBAS® AmpliPrep/COBAS® TaqMan® CMV Test." (NCT01769170)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Brincidofovir | 155 |
| Placebo | 78 |
The primary efficacy endpoint was a binomial outcome of failure to prevent cytomegalovirus (CMV) infection defined as CMV DNAemia >200 copies/mL obtained at the time of the last treatment with study drug or diagnosis of CMV disease at some point during the treatment phase. (NCT00942305)
Timeframe: Randomization to Week 8 post-treatment (~19 weeks)
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 BCV | 13 |
| Cohort 1 Placebo | 4 |
| Cohort 2 BCV | 6 |
| Cohort 2 Placebo | 4 |
| Cohort 3 BCV | 12 |
| Cohort 3 Placebo | 4 |
| Cohort 4 BCV | 7 |
| Cohort 4 Placebo | 3 |
| Cohort 4a BCV | 5 |
| Cohort 4a Placebo | 7 |
22 reviews available for cytosine and Cytomegalovirus
| Article | Year |
|---|---|
Brincidofovir: A Novel Agent for the Treatment of Smallpox.
Topics: Animals; Antiviral Agents; Cytomegalovirus; Cytosine; Disease Models, Animal; Hematopoietic Stem Cel | 2023 |
Antiviral drug resistance in herpesviruses other than cytomegalovirus.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; Drug Resistance, Viral; Foscarnet | 2014 |
Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update.
Topics: Acetates; Antiviral Agents; Benzimidazoles; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; H | 2014 |
Cytomegalovirus.
Topics: Acetates; Antiviral Agents; Benzimidazoles; Bone Marrow Transplantation; Cytomegalovirus; Cytomegalo | 2014 |
Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies.
Topics: Acetates; Adoptive Transfer; Animals; Antiviral Agents; Benzimidazoles; Cell- and Tissue-Based Thera | 2015 |
Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.
Topics: Acetates; Adult; Animals; Antiviral Agents; Asymptomatic Diseases; Benzimidazoles; Clinical Trials a | 2016 |
Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals.
Topics: Adenine; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; Herpesvirus 3, Human; Humans; Nucle | 2017 |
[Gastrointestinal cytomegalovirus infections in organ transplant patients].
Topics: Acyclovir; Antiviral Agents; Biopsy; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosin | 2008 |
Antiviral drug resistance of human cytomegalovirus.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2010 |
The search for new therapies for human cytomegalovirus infections.
Topics: Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; F | 2011 |
Prevention and management of CMV-related problems after hematopoietic stem cell transplantation.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Fosca | 2002 |
Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Cidofovir; Cytomegaloviru | 2004 |
[Mechanism of drug-resistance in human cytomegalovirus].
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2007 |
Cidofovir.
Topics: Animals; Antiviral Agents; Cidofovir; Clinical Trials as Topic; Cytomegalovirus; Cytomegalovirus Ret | 1996 |
Therapeutic options for resistant cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus | 1997 |
Resistance to antivirals in human cytomegalovirus: mechanisms and clinical significance.
Topics: Antiviral Agents; Cidofovir; Codon; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 1997 |
[Recent advances in antiviral drugs--antiviral agents to HCMV, HHV-6, and HHV-7].
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 1998 |
Cidofovir. Review of current and potential clinical uses.
Topics: AIDS-Related Opportunistic Infections; Animals; Antiviral Agents; Cidofovir; Clinical Trials as Topi | 1999 |
Cytomegalovirus infection following stem cell transplantation.
Topics: Acyclovir; Antibodies, Viral; Antiviral Agents; Blood Donors; Cidofovir; Cytomegalovirus; Cytomegalo | 1999 |
Progress in understanding cytomegalovirus drug resistance.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
Cytomegalovirus drug resistance and clinical implications.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
Value of animal models to evaluate agents with potential activity against human cytomegalovirus.
Topics: Acyclovir; Animals; Antiviral Agents; Cell Division; Cell Survival; Cells, Cultured; Cidofovir; Cyto | 1991 |
6 trials available for cytosine and Cytomegalovirus
| Article | Year |
|---|---|
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
Topics: Administration, Oral; Adolescent; Adult; Aged; Allografts; Cytomegalovirus; Cytomegalovirus Infectio | 2019 |
CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.
Topics: Administration, Oral; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Cytosine | 2013 |
Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis.
Topics: Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA Polymerase | 2016 |
Short-term clinical safety profile of brincidofovir: A favorable benefit-risk proposition in the treatment of smallpox.
Topics: Adenoviridae; Adolescent; Adult; Animals; Antiviral Agents; Cytomegalovirus; Cytosine; Disease Model | 2017 |
Susceptibility of human cytomegalovirus to cidofovir is unchanged after limited in vivo exposure to various regimens of drug.
Topics: Adult; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, Microbial; | 1996 |
Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resistance, | 2001 |
114 other studies available for cytosine and Cytomegalovirus
| Article | Year |
|---|---|
[Resistance to antiviral drugs in human viruses from the subfamily
Topics: Antiviral Agents; Betaherpesvirinae; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; Drug Re | 2022 |
[Resistance to antiviral drugs in human viruses from the subfamily
Topics: Antiviral Agents; Betaherpesvirinae; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; Drug Re | 2022 |
[Resistance to antiviral drugs in human viruses from the subfamily
Topics: Antiviral Agents; Betaherpesvirinae; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; Drug Re | 2022 |
[Resistance to antiviral drugs in human viruses from the subfamily
Topics: Antiviral Agents; Betaherpesvirinae; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; Drug Re | 2022 |
Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus.
Topics: Acetates; Antiviral Agents; Artemisinins; Benzimidazoles; Cidofovir; Cytomegalovirus; Cytomegaloviru | 2019 |
Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2017 |
Ganciclovir Dosing Strategies and Development of Cytomegalovirus Resistance in a Kidney Transplant Recipient: A Case Report.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Dose-Respo | 2017 |
Intracellular trafficking and therapeutic outcome of multiwalled carbon nanotubes modified with cyclodextrins and polyethylenimine.
Topics: Animals; Antiviral Agents; beta-Cyclodextrins; Biological Transport; Chlorocebus aethiops; Cidofovir | 2018 |
In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus.
Topics: Antiviral Agents; Benzimidazoles; Cell Line; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovi | 2018 |
Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Cells, Cultured; Chromosomes, Artificial, Bact | 2013 |
Generation and characterization of a GCV resistant HCMV UL97-mutation and a drug sensitive UL54-mutation.
Topics: Antiviral Agents; Chromosomes, Artificial, Bacterial; Cidofovir; Cytomegalovirus; Cytomegalovirus In | 2013 |
Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives.
Topics: Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytosine; Drug Resistance, Multiple, Vi | 2014 |
UL54 foscarnet mutation in an hematopoietic stem cell transplant recipient with cytomegalovirus disease.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2014 |
Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2014 |
Development of CMX001 (Brincidofovir) for the treatment of serious diseases or conditions caused by dsDNA viruses.
Topics: Adenoviridae; Antiviral Agents; Cytomegalovirus; Cytosine; DNA Virus Infections; Humans; Microbial S | 2014 |
Identification of newly detected, drug-related HCMV UL97- and UL54-mutations using a modified plaque reduction assay.
Topics: Adult; Antiviral Agents; Cell Line; Child; Chromosomes, Artificial, Bacterial; Cidofovir; Cytomegalo | 2015 |
Contrasting effect of new HCMV pUL54 mutations on antiviral drug susceptibility: Benefits and limits of 3D analysis.
Topics: Antiviral Agents; Chromosomes, Artificial, Bacterial; Cytomegalovirus; Cytosine; DNA-Directed DNA Po | 2016 |
Novel Cytomegalovirus UL54 DNA Polymerase Gene Mutations Selected In Vitro That Confer Brincidofovir Resistance.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2016 |
Identification of resistance-associated HCMV UL97- and UL54-mutations and a UL97-polymporphism with impact on phenotypic drug-resistance.
Topics: Adolescent; Adult; Antiviral Agents; Child; Chromosomes, Artificial, Bacterial; Cidofovir; Cytomegal | 2016 |
The use of brincidofovir for the treatment of mixed dsDNA viral infection.
Topics: Adult; Antiviral Agents; BK Virus; Coinfection; Cytomegalovirus; Cytosine; DNA Virus Infections; Fat | 2016 |
Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience.
Topics: Aged; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2016 |
Synthesis and Ativiral Activity of 5-(Benzylthio)-4-carbamyl-1,2,3-triazoles Against Human Cytomegalovirus (CMV) and Varicella-zoster Virus (VZV).
Topics: Acyclovir; Antiviral Agents; Bromodeoxyuridine; Cidofovir; Cytomegalovirus; Cytosine; Ganciclovir; H | 2017 |
Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Topics: Alemtuzumab; Anemia, Refractory, with Excess of Blasts; Antibodies, Monoclonal; Antibodies, Monoclon | 2008 |
New prodrugs of Adefovir and Cidofovir.
Topics: Adenine; Animals; Antiviral Agents; Cell Line, Tumor; Cidofovir; Cytomegalovirus; Cytosine; Herpesvi | 2011 |
Synthesis, transport and antiviral activity of Ala-Ser and Val-Ser prodrugs of cidofovir.
Topics: Administration, Oral; Alanine; Animals; Antiviral Agents; Cells, Cultured; Cidofovir; Cytomegaloviru | 2011 |
Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.
Topics: Adenine; Animals; Antiviral Agents; Area Under Curve; Biological Availability; Cell Line, Tumor; Cel | 2011 |
Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure.
Topics: Alkaline Phosphatase; Antiviral Agents; Cidofovir; Cyclopropanes; Cytomegalovirus; Cytomegalovirus I | 2012 |
Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cytosine; DNA, Viral | 2012 |
Case report: Multidrug-resistant cytomegalovirus in a modified multivisceral transplant recipient.
Topics: Adult; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Resi | 2012 |
Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro.
Topics: Animals; Antiviral Agents; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytosine; Fibroblasts; Guine | 2002 |
Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation.
Topics: Acyclovir; Antiviral Agents; Chemoprevention; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections | 2002 |
Synthesis and anti-HCMV activity of novel acyclic nucleosides.
Topics: Adenine; Antiviral Agents; Cell Line; Cytomegalovirus; Cytosine; Humans; Lactose; Microbial Sensitiv | 2002 |
Synergy of bovine lactoferrin with the anti-cytomegalovirus drug cidofovir in vitro.
Topics: Acyclovir; Animals; Antiviral Agents; Cattle; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytosine; | 2003 |
An animal model of neonatal cytomegalovirus infection.
Topics: Animals; Animals, Newborn; Antiviral Agents; Body Weight; Brain; Cytomegalovirus; Cytomegalovirus In | 2003 |
Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.
Topics: Antigens, Viral; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cidofovir; Cyto | 2004 |
Comparison of sequential cytomegalovirus isolates in a patient with lymphoma and failing antiviral therapy.
Topics: Aged; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA, Viral | 2004 |
Susceptibility of porcine cytomegalovirus to antiviral drugs.
Topics: Animals; Antiviral Agents; Cell Survival; Cidofovir; Cytomegalovirus; Cytosine; DNA, Viral; Fluoresc | 2004 |
Efficacy of ganciclovir and cidofovir against human cytomegalovirus replication in SCID mice implanted with human retinal tissue.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cytosine; Disease | 2004 |
Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection.
Topics: Administration, Oral; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infecti | 2004 |
Expression of a transgene encoded on a non-viral episomal vector is not subject to epigenetic silencing by cytosine methylation.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Cytomegalovirus; Cytosine; DNA Methylation; Epigenesis, | 2004 |
Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Esters; | 2004 |
Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.
Topics: Antiviral Agents; Blotting, Western; Cell Line; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytosin | 2004 |
Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro.
Topics: Animals; Anti-HIV Agents; Cells, Cultured; Cidofovir; Coloring Agents; Cytomegalovirus; Cytosine; Es | 2005 |
Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus.
Topics: Acyclovir; Adenine; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; DNA-Directed DN | 2005 |
Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro.
Topics: Antiviral Agents; Cell Adhesion; Cell Proliferation; Cell Survival; Cells, Cultured; Cidofovir; Cycl | 2005 |
New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.
Topics: Amino Acid Sequence; Antiviral Agents; Cell Line; Cidofovir; Cytomegalovirus; Cytosine; DNA Replicat | 2005 |
Inhibition of the replication of DNA viruses by phosphonylmethoxyalkyl-purines and -pyrimidines.
Topics: Adenine; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; DNA Viruses; Organophosphonates; Si | 1989 |
Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection.
Topics: Animals; Animals, Newborn; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; | 2006 |
Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet.
Topics: Antiviral Agents; Benzimidazoles; Cidofovir; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; | 2006 |
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA Replication; | 2007 |
Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Drug Therapy, Co | 2007 |
A model of human cytomegalovirus infection in severe combined immunodeficient mice.
Topics: Animals; Antiviral Agents; Cell Culture Techniques; Cell Line; Cidofovir; Cytomegalovirus; Cytomegal | 2007 |
Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Cells, Cultured; Cid | 2008 |
Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models.
Topics: Adenine; Administration, Oral; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegaloviru | 2008 |
Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA-Directed DNA | 2008 |
A rapid protein A binding radioimmunoassay for the evaluation of antiviral agents.
Topics: Antiviral Agents; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytosine; Evaluation Studies as Topic | 1994 |
Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system.
Topics: Antiviral Agents; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytosine; Half-Life; Humans; Organoph | 1994 |
New inhibitors of cytomegalovirus replication: in vitro evaluation, mechanism of action, and in vivo activity.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine | 1994 |
Synthesis of galactosyl phosphate diester derivatives of nucleosides.
Topics: Adenine; Antiviral Agents; Cytomegalovirus; Cytosine; HIV; Humans; Indicators and Reagents; Magnetic | 1994 |
Rat cytomegalovirus-induced pneumonitis after allogeneic bone marrow transplantation: effective treatment with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine.
Topics: Animals; Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Cidofovir; Cytomegalovirus; | 1993 |
Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice.
Topics: Animals; Animals, Newborn; Antiviral Agents; Brain; Brain Diseases; Cidofovir; Cytomegalovirus; Cyto | 1993 |
Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase.
Topics: Animals; Antiviral Agents; Base Sequence; Cattle; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytom | 1996 |
Current and experimental therapeutic options for cytomegalovirus disease.
Topics: Administration, Oral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cyto | 1996 |
Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro.
Topics: Acyclovir; Adenine; Antiviral Agents; Cells, Cultured; Cidofovir; Cytarabine; Cytomegalovirus; Cytom | 1996 |
Imbalance in production of cytokines by bone marrow stromal cells following cytomegalovirus infection.
Topics: Bone Marrow Cells; Cidofovir; Cytokines; Cytomegalovirus; Cytosine; Ganciclovir; Humans; Lipopolysac | 1996 |
Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; DNA Primers; DNA-Directed DNA Polymerase; DN | 1997 |
Genetic analysis of a clinical isolate of human cytomegalovirus exhibiting resistance against both ganciclovir and cidofovir.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA, Viral; Drug | 1997 |
High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; DNA-Directed DNA Polymerase; Drug Resistance | 1997 |
Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cidofovir; Cytomega | 1997 |
Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomega | 1998 |
Interpreting human cytomegalovirus antiviral drug susceptibility testing: the role of mixed virus populations.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; Drug Resistance, Microbial; Foscarnet; Ganci | 1998 |
Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; A | 1998 |
Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; DNA Replication; DNA-Directed DNA Polymerase | 1998 |
A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture.
Topics: Amino Acid Sequence; Antiviral Agents; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytosine; DNA Re | 1998 |
[Comparison of the in vitro sensitivity to cidofovir and ganciclovir of clinical cytomegalovirus isolates. Coordinated Action Group 11].
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; Drug Resistance, Microbial; Drug Resistance, | 1998 |
Cytomegalovirus retinitis and viral resistance: 3. Culture results. CMV Retinitis and Viral Resistance Study Group.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Baltimore; Blood; Cidofovir; Cytomeg | 1998 |
In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cytosine; Drug Resistance, | 1998 |
Cytomegalovirus iritis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibodies, Viral; Antigens, Viral; Antiviral Agents; | 1998 |
Comparative study of the anti-human cytomegalovirus activities and toxicities of a tetrahydrofuran phosphonate analogue of guanosine and cidofovir.
Topics: Animals; Antiviral Agents; Cell Line; Cell Survival; Cidofovir; Cytomegalovirus; Cytosine; Guanine; | 1999 |
A high throughput colorimetric cell proliferation assay for the identification of human cytomegalovirus inhibitors.
Topics: Antiviral Agents; Cidofovir; Colorimetry; Cytomegalovirus; Cytopathogenic Effect, Viral; Cytosine; F | 1999 |
Comment: cidofovir in the treatment of cytomegaloviral disease.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Organophosphonat | 1999 |
Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus In | 1999 |
Lack of reactivation of cytomegalovirus retinitis in an AIDS patient, during and after stopping long-term cidofovir treatment: case report.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomega | 2000 |
Thienothiadiazine 2,2-dioxide acyclonucleosides: synthesis and antiviral activity.
Topics: Antiviral Agents; Cells, Cultured; Cytomegalovirus; Cytosine; Fibroblasts; Herpesvirus 3, Human; HIV | 2000 |
Treatment of BK virus-associated hemorrhagic cystitis and simultaneous CMV reactivation with cidofovir.
Topics: Antiviral Agents; BK Virus; Cidofovir; Cystitis; Cytomegalovirus; Cytomegalovirus Infections; Cytosi | 2000 |
A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Re | 2000 |
Fatal cytomegalovirus pneumonia after preemptive antiviral therapy in a renal transplant recipient.
Topics: Antigens, Viral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; | 2000 |
Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation.
Topics: Adult; Antiviral Agents; Chronic Disease; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis; Cyt | 2001 |
Enhancement of transplantation-associated atherosclerosis by CMV, which can be prevented by antiviral therapy in the form of HPMPC.
Topics: Animals; Antiviral Agents; Aorta; Arteriosclerosis; Cidofovir; Cytomegalovirus; Cytomegalovirus Infe | 1994 |
Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation.
Topics: Adult; Antigens, Viral; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cy | 2001 |
CMV retinitis: a clinical management update.
Topics: AIDS-Related Opportunistic Infections; Algorithms; Antiviral Agents; Cidofovir; Clinical Protocols; | 1996 |
Strategies for management of cytomegalovirus (CMV) infection after allogeneic bone marrow transplantation: the "doubling of baseline CMV pp65 antigenemia" and the "cidofovir as rescue treatment approaches.
Topics: Antigens, Viral; Antiviral Agents; Bone Marrow Transplantation; Child; Cidofovir; Cytomegalovirus; C | 2001 |
Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients.
Topics: Adult; Antiviral Agents; Cell Culture Techniques; Cidofovir; Cytomegalovirus; Cytomegalovirus Infect | 2001 |
Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Disease | 2001 |
Cidofovir as primary pre-emptive therapy for post-transplant cytomegalovirus infections.
Topics: Adult; Antiviral Agents; Cidofovir; Cyclosporine; Cytomegalovirus; Cytomegalovirus Infections; Cytos | 2001 |
Polymerase chain reaction-based "pre-emptive" therapy with cidofovir for cytomegalovirus reactivation in allogeneic hematopoietic stem cells transplantation recipients: a prospective study.
Topics: Adult; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; DNA, Viral; Hematopoietic S | 2002 |
Antiviral and immunomodulatory activity of the metal chelator ethylenediaminedisuccinic acid against cytomegalovirus in vitro and in vivo.
Topics: Adjuvants, Immunologic; Animals; Antiviral Agents; Cell Adhesion; Cell Line; Chelating Agents; Cidof | 2002 |
In vitro antiviral activity of aphidicolin and its derivates. Synergistic effects of aphidicolin with other antiviral drugs.
Topics: Adenoviridae; Antiviral Agents; Aphidicolin; Cidofovir; Cytomegalovirus; Cytosine; Dose-Response Rel | 2002 |
Human cytomegalovirus genome: partial denaturation map and organization of genome sequences.
Topics: Base Sequence; Cytomegalovirus; Cytosine; DNA, Viral; Genes, Viral; Guanine; Humans; Molecular Weigh | 1977 |
Pretreatment of the host cell with 1-(S)-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) is sufficient for its antiviral effect.
Topics: Antigens, Viral; Antiviral Agents; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytopathogenic Effec | 1992 |
Phosphonomethylether compounds as antiviral agents.
Topics: Animals; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; Haplorhini; Herpes Simplex; Mice; O | 1991 |
Antiviral activity of anti-cytomegalovirus agents (HPMPC, HPMPA) assessed by a flow cytometric method and DNA hybridization technique.
Topics: Adenine; Antiviral Agents; Cell Line; Cidofovir; Cytomegalovirus; Cytosine; Flow Cytometry; Ganciclo | 1991 |
Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro.
Topics: Animals; Antiviral Agents; Cidofovir; Cytarabine; Cytidine; Cytomegalovirus; Cytosine; Deoxycytidine | 1991 |
Sensitive, reproducible and convenient fluorometric assay for the in vitro evaluation of anti-cytomegalovirus agents.
Topics: Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; Cytosine; Ester | 1991 |
Comparative activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine against rat cytomegalovirus infection in vitro and in vivo.
Topics: Animals; Antiviral Agents; Cell Survival; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytomegalovir | 1991 |
Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro.
Topics: Adenine; Adenosine; Antiviral Agents; Cell Line; Cidofovir; Cytidine; Cytomegalovirus; Cytosine; Gan | 1991 |
Synthesis and antiviral activity of (S)-9-[4-hydroxy-3-(phosphonomethoxy)butyl]guanine.
Topics: Adenine; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; Guanine; Organophosphonates; Organo | 1990 |
Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs.
Topics: Animals; Antiviral Agents; Cells, Cultured; Cidofovir; Cytomegalovirus; Cytomegalovirus Infections; | 1990 |
Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro.
Topics: Adenine; Adult; Antiviral Agents; Bone Marrow; Bone Marrow Cells; Cells, Cultured; Cidofovir; Cytome | 1990 |
Selective inhibition of human cytomegalovirus DNA synthesis by (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [(S)-HPMPC] and 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG).
Topics: Antiviral Agents; Cell Line; Cell Survival; Cidofovir; Cytomegalovirus; Cytosine; DNA; DNA Replicati | 1990 |
Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine.
Topics: Animals; Antiviral Agents; Chemical Phenomena; Chemistry; Cidofovir; Cytomegalovirus; Cytosine; Cyto | 1989 |
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, a potent and selective inhibitor of human cytomegalovirus replication.
Topics: Antiviral Agents; Cidofovir; Cytomegalovirus; Cytosine; Humans; Organophosphonates; Organophosphorus | 1988 |
Some properties of the genome of murine cytomegalovirus (MCV).
Topics: Animals; Carbon Isotopes; Carcinoma; Cell Line; Centrifugation, Density Gradient; Coliphages; Cultur | 1973 |
A comparative study of the DNA density and behavior in tissue cultures of fourteen different herpesviruses.
Topics: Animals; Cats; Cattle; Cell Line; Culture Techniques; Cytomegalovirus; Cytosine; Densitometry; DNA, | 1969 |
Marek's disease herpes virus: a cytomegalovirus.
Topics: Animals; Avian Leukosis; Avian Leukosis Virus; Centrifugation, Density Gradient; Chick Embryo; Chick | 1969 |
[Genetic material of herpesviruses. I. Biophysical-chemical characterization of herpesvirus DNAs].
Topics: Animals; Anura; Cats; Cattle; Centrifugation, Density Gradient; Centrifugation, Zonal; Chickens; Cyt | 1972 |
Structural and functional heterogeneity of the murine cytomegalovirus genome.
Topics: Animals; Carbon Radioisotopes; Cells, Cultured; Centrifugation, Density Gradient; Culture Techniques | 1974 |